Tyme Technologies Inc

Tyme Technologies — Corporate Update (July 2019)

21 slides from Tyme Technologies's corporate update, Jul 9, 2019

  1. Slide 1: ESMO GI Conference Call

    ESMO GI Conference Call July 9, 2019 NASDAQ: TYME Exhibit 99.1

  2. Slide 2: TYME Conference Call Participants

    TYME Conference Call Participants General Comments Steve Hoffman, Chairman & Chief Executive Officer Overview of TYME-88-Panc Study Michele Korfin, RPh, MBA, Chief Operating Officer ESMO GI Results Giuseppe Del Priore, MD, MPH, Chief Medical Officer Observations from a Key Opinion Leader Manuel Hida

  3. Slide 3: Safe Harbor Statement

    YA, oa Safe Harbor Statement In addition to historical information, this presentation contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. Such forward-looking statements within this presentation include, without lim

  4. Slide 4: TYME Technologies

    TYME Technologies TYME is an emerging biotechnology company focused on exploring novel therapeutic approaches designed to target cancer’s unique metabolism TYME is advancing proprietary Cancer Metabolism Based Therapies (CMBTs™) for difficult-to-treat cancers

  5. Slide 5: General Comments on TYME-88-Panc Study

    GENERAL COMMENTS ON TYME-88-PANC Study Steve Hoffman, Chairman & Chief Executive Officer

  6. Slide 6: Key Takeaways

    Key Takeaways Median overall survival of 6.4 months as of April 25, 2019 in this poor prognosis population Patients who achieved stable disease or better had a statistically significant (p=0.02) improvement in survival with a 92% reduction in risk of death Patients who achieved at least an 80% reduc

  7. Slide 7: Overview of TYME-88-Panc Study

    OVERVIEW OF TYME-88-PANC STUDY Michele Korfin, RPh, MBA, Chief Operating Officer

  8. Slide 8: TYME-88-Panc Overview

    TYME-88-Panc Overview SM-88 has demonstrated encouraging efficacy and a well-tolerated safety profile in 15 different tumor types, including solid tumors and hematologic malignancies across four separate studies and ~ 200 patients​ SM-88 is our lead investigational therapy in the TYME Cancer Metabol

  9. Slide 9: TYME-88-Panc Overview: Focus on 3rd line patients

    Focus on 3rd line patients Trial design will reflect FDA protocol evaluation Randomized with overall survival as primary endpoint SM-88 Monotherapy in Patients with Radiographically Progressing Metastatic Pancreatic Cancer (Phase II/III) Structure: Part 1 single-arm, Part 2 randomized Sites: ~25 cur

  10. Slide 10: TYME-88-Panc Data from ESMO GI

    TYME-88-panc Data from ESMO GI Giuseppe Del Priore, MD, MPH, Chief Medical Officer

  11. Slide 11: TYME-88-Panc Overall Survival (OS)

    TYME-88-Panc Overall Survival (OS) Refractory PDAC has no established therapy. Previously reported survival for third line PDAC patients is approximately 2.0 – 2.5 months (Manax et al. ASCO GI Poster 2019) The preliminary median Kaplan-Meier (KM) derived overall survival of the evaluable population

  12. Slide 12: TYME-88-Panc Clinical Benefit Rate (CBR)

    TYME-88-Panc Clinical Benefit Rate (CBR) 44% (11/25) RECIST Clinical Benefit Rate (SD or PR) Patients who achieved at least SD by first assessment demonstrated statistically significant greater survival than PD patients Patients demonstrated a 92% reduction in risk of death HR: 0.08 (95% CI 0.01 – 0

  13. Slide 13: TYME-88-Panc Circulating Tumor Cells (CTCs)

    TYME-88-Panc Circulating Tumor Cells (CTCs) HR: 0.4 95%CI (0.11 – 1.5) p = 0.18 Best CTC Response by % Reduction (n=24) Emerging biomarker in pancreatic cancer Patients who had at least an 80% CTC reduction trended towards greater survival These patients demonstrated a 60% decrease in risk of death

  14. Slide 14: Ongoing Favorable Safety Profile

    Ongoing Favorable Safety Profile Compared with Other Treatments in this Patient Population SM-88 was well tolerated with only 4.0% of patients (2 of 49) reporting serious adverse events (SAEs) deemed at least possibly related to SM-88 SM-88 has demonstrated a favorable safety profile in 15 different

  15. Slide 15: A Key Opinion Leader's Perspective

    A KEY OPINION LEADER’S PERSEPCTIVE Manuel Hidalgo, MD, Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and New York-Presbyterian/ Weill Cornell Medical Center

  16. Slide 16: A Perspective from Manuel Hidalgo, MD

    A Perspective from Manuel Hidalgo, MD SM-88 OS trend is encouraging in this poor prognosis patient population Several promising efficacy markers (reduction in CTCs; achieving SD or better) correlate with greater survival Further investigation should be conducted into the prognostic indicators associ

  17. Slide 17: Next Steps to Initiating our Pivotal Study

    Next Steps to Initiating our Pivotal Study Michele Korfin, RPh, MBA, Chief Operating Officer

  18. Slide 18: TYME-88-Panc Pivotal Trial Design

    ENDPOINT(S) DESIGN TYME-88-Panc Pivotal Trial Design PHASE II/III SM-88 used with MPS in Patients with Metastatic Adenocarcinoma of the Pancreas Who’s Disease Has Progressed or Reoccurred Study Identifier: NCT03512756 Histologically confirmed pancreatic adenocarcinoma Received 2 lines of prior syste

  19. Slide 19: Summary Comments

    Summary Comments Steve Hoffman, Chairman & Chief Executive Officer

  20. Slide 20: TYME: Delivering on Our Vision

    Delivering first-in-class oral approach to kill cancer cells Leveraging high barrier to entry with CMBTsTM and strong patents TYME: Delivering on Our Vision Targeting difficult-to-treat cancers with limited options Addressing opportunities in large growing markets STRATEGY Advancing cost-efficient p

  21. Slide 21: TYMEO State Street 7™ FLOOR

    TYMEO 17 State Street 7™ FLOOR NEW YORK, NY 10004 NASDAQ: TYME INFO@TYMEINC.COM TYMEINC.COM

TYME Technologies — Corporate Update (July 2019) on 6ix